Restricted fluid bolus volume in early septic shock: results of the Fluids in Shock pilot trial.


Journal

Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434

Informations de publication

Date de publication:
05 2019
Historique:
received: 06 02 2018
revised: 10 07 2018
accepted: 15 07 2018
pubmed: 9 8 2018
medline: 24 1 2020
entrez: 9 8 2018
Statut: ppublish

Résumé

To determine the feasibility of Fluids in Shock, a randomised controlled trial (RCT) of restricted fluid bolus volume (10 mL/kg) versus recommended practice (20 mL/kg). Nine-month pilot RCT with embedded mixed-method perspectives study. 13 hospitals in England. Children presenting to emergency departments with suspected infection and shock after 20 mL/kg fluid. Patients were randomly allocated (1:1) to further 10 or 20 mL/kg fluid boluses every 15 min for up to 4 hours if still in shock. These were based on progression criteria, including recruitment and retention, protocol adherence, separation, potential trial outcome measures, and parent and staff perspectives. Seventy-five participants were randomised; two were withdrawn. 23 (59%) of 39 in the 10 mL/kg arm and 25 (74%) of 34 in the 20 mL/kg arm required a single trial bolus before the shock resolved. 79% of boluses were delivered per protocol in the 10 mL/kg arm and 55% in the 20 mL/kg arm. The volume of study bolus fluid after 4 hours was 44% lower in the 10 mL/kg group (mean 14.5 vs 27.5 mL/kg). The Paediatric Index of Mortality-2 score was 2.1 (IQR 1.6-2.7) in the 10 mL/kg group and 2.0 (IQR 1.6-2.5) in the 20 mL/kg group. There were no deaths. Length of hospital stay, paediatric intensive care unit (PICU) admissions and PICU-free days at 30 days did not differ significantly between the groups. In the perspectives study, the trial was generally supported, although some problems with protocol adherence were described. Participants were not as unwell as expected. A larger trial is not feasible in its current design in the UK. ISRCTN15244462.

Identifiants

pubmed: 30087153
pii: archdischild-2018-314924
doi: 10.1136/archdischild-2018-314924
pmc: PMC6557227
doi:

Banques de données

ISRCTN
['ISRCTN15244462']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

426-431

Subventions

Organisme : Department of Health
ID : HTA/13/04/105
Pays : United Kingdom
Organisme : Department of Health
ID : HTA/15/44/01
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Crit Care. 2012 Jan 25;16(1):302
pubmed: 22277834
Crit Care Res Pract. 2011;2011:854142
pubmed: 21687578
Arch Dis Child. 2009 May;94(5):348-53
pubmed: 19131419
Pediatr Crit Care Med. 2015 Jun;16(5):410-7
pubmed: 25739013
Pediatr Crit Care Med. 2015 Mar;16(3):205-9
pubmed: 25581632
Arch Dis Child Educ Pract Ed. 2016 Feb;101(1):49-53
pubmed: 26464416
J Clin Epidemiol. 2012 Mar;65(3):301-8
pubmed: 22169081
Crit Care Med. 2017 Jun;45(6):1061-1093
pubmed: 28509730
Crit Care Med. 2012 Oct;40(10):2883-9
pubmed: 22824936
Pediatr Emerg Care. 2008 Oct;24(10):647-55
pubmed: 19242131
N Engl J Med. 2011 Jun 30;364(26):2483-95
pubmed: 21615299
Pediatrics. 2003 Oct;112(4):793-9
pubmed: 14523168
Crit Care Med. 2009 Jan;37(1 Suppl):S65-8
pubmed: 19104227
Lancet Child Adolesc Health. 2018 Jun;2(6):404-414
pubmed: 30169282
BMJ Open. 2015 Sep 18;5(9):e008522
pubmed: 26384724
Lancet. 2016 Dec 3;388(10061):2775-2782
pubmed: 28100432
Arch Dis Child. 2018 Jan;103(1):28-32
pubmed: 28847877
BMC Med. 2013 Mar 14;11:67
pubmed: 23497460
Arch Dis Child. 2014 Jun;99(6):602-3
pubmed: 24615624
Intensive Care Med. 2015 Aug;41(8):1457-9
pubmed: 26088913
Trials. 2011 Mar 31;12:90
pubmed: 21453454
Intensive Care Med. 2003 Feb;29(2):278-85
pubmed: 12541154
Arch Dis Child. 2001 Nov;85(5):386-90
pubmed: 11668100
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
JAMA. 1991 Sep 4;266(9):1242-5
pubmed: 1870250
J Med Ethics. 2011 Jul;37(7):429-32
pubmed: 21345861
PLoS One. 2013;8(2):e54894
pubmed: 23408950
Intensive Care Med. 2015 Aug;41(8):1445-53
pubmed: 26077052
BMC Med Ethics. 2013 Nov 06;14:45
pubmed: 24195717
Pediatr Crit Care Med. 2015 Oct;16(8):e297-307
pubmed: 26203624
Crit Care Med. 2009 Feb;37(2):666-88
pubmed: 19325359

Auteurs

David Philip Inwald (DP)

Paediatric Intensive Care Unit, St Mary's Hospital, Imperial College Healthcare London NHS Trust, London, UK.

Ruth Canter (R)

Clinical Trials Unit, Intensive Care National Audit & Research Centre, London, UK.

Kerry Woolfall (K)

Department of Psychological Sciences, North West Hub for Trials Methodology, University of Liverpool, Liverpool, UK.

Paul Mouncey (P)

Clinical Trials Unit, Intensive Care National Audit & Research Centre, London, UK.

Zohra Zenasni (Z)

Clinical Trials Unit, Intensive Care National Audit & Research Centre, London, UK.

Caitlin O'Hara (C)

Department of Psychological Sciences, North West Hub for Trials Methodology, University of Liverpool, Liverpool, UK.

Anjali Carter (A)

Parent representative.

Nicola Jones (N)

Parent representative.

Mark D Lyttle (MD)

Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK.
Emergency Department, Bristol Royal Hospital for Children, Bristol, UK.

Simon Nadel (S)

Paediatric Intensive Care Unit, St Mary's Hospital, Imperial College Healthcare London NHS Trust, London, UK.

Mark J Peters (MJ)

Respiratory, Critical Care and Anaesthesia Section, Institute of Child Health, University College London Great Ormond Street, London, UK.

David A Harrison (DA)

Clinical Trials Unit, Intensive Care National Audit & Research Centre, London, UK.

Kathryn M Rowan (KM)

Clinical Trials Unit, Intensive Care National Audit & Research Centre, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH